50/170 micrograms per 24 hours transdermal patch
estradiol hemihydrate and norethisterone acetate
Evorel Conti- Continuous combined therapy.(3.2mg estradiol / 11.2mg norethisterone acetate patches). Indicated for
- HRT in post-menopausal women, more than 6 months post menopause. (18 months since last period)
50 micrograms per 24 hours transdermal patch
estradiol hemihydrate
Evorel 50- Oestrogen only therapy (3.2mg estradiol patches). Indicated for
- HRT for oestrogen deficiency symptoms in postmenopausal women.
- Prevention of osteoporosis in postmenopausal women at high risk of future fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis
WHEN TO USE THE EVOREL® RANGE1,2
Systemic HRT treatment for Post-Menopausal Women
Adapted from HRT – Guide, British Menopause Society Tool for Clinicians4
* Post-menopausal women more than 6 months post menopause (or 18 months since last period)
References
- Evorel 50 Patch Summary of product characteristics available on medicines.ie
- Evorel Conti Patch Summary of product characteristics available on medicines.ie
- NICE Guidelines. Menopause: diagnosis and management. https://www.nice.org.uk/guidance/ng23/resources/menopause-diagnosis-and-management-pdf-1837330217413, accessed October 2022
- British Menopause Society Tool for Clinicians, HRT Guide, https://thebms.org.uk/wp-content/uploads/2022/08/04-BMS-TfC-HRT-Guide-01-AUGUST2022-A.pdf, accessed October 2022.
